For a new complex biologic therapeutic, developing a robust, high-yielding cell line is a foundational step in the development journey to IND. However, the path to a successful cell line isn’t always straightforward and can be a complex, timely and multi-faceted process that requires careful planning, integration and execution.
At Abzena, our two decades of expertise in CLD coupled with our state-of-the-art technologies ensures that every step of the process is meticulously planned and executed to meet the specific needs of each biologic, so that your pathway to the clinic is de-risked and streamlined.
Our AbZelectPRO™ cell line platforms offer biopharma customers a solution with higher productivity, rapid timelines and proven performance, all without the frustration of royalty or exit fees.
Download the PDF to read more.
